# Melanotan Dosage in the Research Literature

> melanotan dosage context from published Phase I trials: 0.025 mg/kg subcutaneous in human ED studies, 0.01–0.03 mg/kg in Phase I pigmentation escalation. Routes, half-life, and reconstitution.

## Phase I Dose-Escalation Data

melanotan dosage in human studies derives from a small number of Phase I trials. The 1996 Dorr pilot study used a 5-day dose escalation in 3 healthy males: 0.01, 0.015, 0.02, 0.025, and 0.03 mg/kg/day subcutaneous [3]. Measurable pigmentation increases were observed in 2 of 3 subjects. Nausea and somnolence were reported at higher dose levels.

Subsequent ED trials by Wessells et al. (1998, 2000) standardized the dose at 0.025 mg/kg subcutaneous — a dose that produced erections in 8 of 10 (psychogenic ED) [5] and 17 of 20 (organic ED) [6] subjects. Erection duration confirmed at approximately 45 minutes vs. 1.9 minutes for placebo [7].

Those three trials constitute the entirety of controlled human dose data for Melanotan II. No Phase II or Phase III trials for MT-II in any indication have been completed.

## Onset Timeline

In Phase I trials, objective colorimetric pigmentation increases were measurable at 2–4 weeks of daily subcutaneous dosing [3]. Self-reported onset in uncontrolled populations describes within-week changes [23]. Only the Phase I Dorr data provides controlled onset measurement.

## Persistence After Cessation

In the Dorr 1996 Phase I trial, pigmentation increases were still measurable 4–6 weeks after the last dose; duration was variable and correlated with baseline Fitzpatrick skin type [3]. Plasma clearance is rapid (MT-I beta half-life 0.8–1.7 hours subcutaneous in humans [17]; MT-II biphasic rapid IV clearance in rats [18]), but melanin synthesis continues after peptide clearance. Research does not support permanent pigmentation.

Reversal timeline: The 2012 Sivyer case report noted skin color paling three months after cessation [14]. The 2026 Bonchev case showed partial reversal of oral mucosal pigmentation by 28 days post-cessation [24].

## Pharmacokinetics and Half-Life

**MT-I in humans (Ugwu 1997):** Absorption phase half-life 0.07–0.79 hours; beta-phase half-life 0.8–1.7 hours subcutaneous; systemic clearance 0.12–0.19 L/kg/h; oral bioavailability undetectable [17]. Pigmentation effects persisted 3 weeks after final dose despite rapid peptide clearance.

**MT-II in rats (Ugwu 1994):** Biphasic plasma disposition confirmed by HPLC and bioassay; rapid multi-compartment clearance [18].

**Oral route:** 4.6% oral bioavailability for MT-II in rats [1]; undetectable for MT-I in humans [17]. Not viable for research use.

## Administration Routes

- **Subcutaneous injection.** Primary research route. All Phase I human trials [3][5][6][7].
- **Intranasal spray.** No controlled trial data. A 2025 case report documented mucosal malignant melanoma of the anterior maxilla following unlicensed MT-II nasal spray use [25]. HPRA and MHRA have issued specific warnings.
- **Subcutaneous biodegradable implant.** The approved route for afamelanotide (Scenesse) in EPP. 16 mg / 60–120 day slow release [15].
- **Oral.** Not viable (4.6% BA in rats; undetectable in humans).

## Reconstitution in Research Protocols

Laboratory protocols for lyophilized MT-II powder typically use bacteriostatic water at 1–2 mg/mL concentrations. Reconstituted solutions stored at 4°C per standard peptide laboratory protocols. Standard cold-chain peptide handling applies.

## References

[1] Lan EL et al. Preformulation studies with melanotan-II. J Pharm Sci. 1994. PMID: 7983590
[3] Dorr RT et al. Evaluation of melanotan-II in a pilot phase-I clinical study. Life Sci. 1996. PMID: 8637402
[5] Wessells H et al. Synthetic melanotropic peptide initiates erections. J Urol. 1998. PMID: 9679884
[6] Wessells H et al. Melanocortin receptor agonists, penile erection. Int J Impot Res. 2000. PMID: 11035391
[7] Wessells H et al. Effect of alpha-MSH analog on penile erection. Urology. 2000. PMID: 11018622
[8] Zhang Y et al. Intermittent MTII application evokes repeated anorexia. Peptides. 2010. PMID: 20034526
[9] Cote I et al. Activation of the central melanocortin system. Can J Physiol Pharmacol. 2017. PMID: 28051332
[14] Sivyer GW. Changes of melanocytic lesions induced by Melanotan. Dermatol Pract Concept. 2012. PMID: 23785612
[15] Langendonk JG et al. Afamelanotide for Erythropoietic Protoporphyria. N Engl J Med. 2015. PMID: 26132941
[17] Ugwu SO et al. Skin pigmentation and pharmacokinetics of melanotan-I. Biopharm Drug Dispos. 1997. PMID: 9113347
[18] Ugwu SO et al. HPLC and bioassay methods for plasma MT-II in rats. Biopharm Drug Dispos. 1994. PMID: 7981427
[23] Gilhooley E et al. Melanotan II User Experience. Dermatology. 2021. PMID: 34464955
[24] Bonchev A. Changes in Oral Mucosa Associated with Melanotan II. Life (Basel). 2026. PMID: 41752902
[25] Alsabbagh AY et al. Melanotan II nasal spray and oral mucosal malignant melanoma. Int J Oral Maxillofac Surg. 2025. PMID: 40210573

---

A drill-down index of the peer-reviewed melanotan record — Phase I trials, preclinical mechanism studies, and documented adverse events, cited to the source.